COSBI Internal Talks
Understanding how innovative therapeutic modalities behave in the body is essential for guiding their development and optimizing their clinical potential. During the latest COSBI Internal Talks, Daniele Boaretti presented his work on the development of a mechanistic PK/PD modeling framework for a CataLYTAC degrader, an emerging class of therapeutics designed to selectively degrade disease-causing extracellular proteins.
The presentation focused on building a quantitative framework capable of describing drug–target interactions, protein suppression dynamics, and the pharmacokinetic and pharmacodynamic processes underlying CataLYTAC-mediated protein degradation. By integrating mechanistic modeling with biological knowledge, the framework aims to support model-informed decisions throughout the drug development process.
The work was developed in collaboration with Roberto Visintainer and Stefano Giampiccolo, combining expertise in pharmacokinetics, pharmacodynamics, and computational modeling to investigate this promising therapeutic strategy.
CataLYTAC degraders belong to the broader family of LYTAC (Lysosome Targeting Chimera) technologies, which promote the lysosomal degradation of extracellular and membrane-associated proteins by exploiting endogenous receptor-mediated internalization pathways. These innovative approaches are attracting growing interest as a new therapeutic modality for diseases driven by pathogenic proteins that are difficult to target using conventional strategies.
As with all COSBI Internal Talks, the seminar provided an opportunity for researchers from different scientific backgrounds to exchange ideas, discuss modeling strategies, and provide constructive feedback on ongoing projects. These regular meetings play an important role in fostering interdisciplinary collaboration and strengthening the institute’s research culture.
We thank Daniele, Roberto, and Stefano for sharing their work and the entire COSBI team for another engaging scientific discussion.
